Lack of association between NOD2 3020insC frameshift mutation and psoriasis [1]

Journal of Investigative Dermatology

Volumn 117, Issue 6, 2001, Pages 1671-1672

  Nair, Rajan P ^a   Stuart, Philip ^a   Ogura, Yasunori ^b,c   Inohara, Naohiro ^b,c   Chia, Nicholas V C ^a   Young, Lily ^a   Henseler, Tilo ^d   Jenisch, Stefan ^d   Christophers, Enno ^d   Voorhees, John J ^a   Nuñez, Gabriel ^b,c   Elder, James T ^a,c,e  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF KIEL   (Germany)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICROSATELLITE DNA; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA;

CROHN DISEASE; FAMILY HISTORY; FRAMESHIFT MUTATION; GENE FREQUENCY; GENE INSERTION; GENE LINKAGE DISEQUILIBRIUM; GENE MAPPING; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC VARIABILITY; HUMAN; LETTER; MAJOR HISTOCOMPATIBILITY COMPLEX; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PSORIASIS;

EID: 0035674155     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0022-202x.2001.01620.x     Document Type: Article

References (22)

1. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis
2. Characterization of the major susceptibility region for psoriasis at chromosome 6p21.3
3. Advances in the search for psoriasis susceptibility genes
4. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomised trial
5. Elevated tumour necrosis factor-α (TNF-α) biological activity in psoriatic skin lesions
6. Sulfasalazine improves psoriasis. A double-blind analysis
7. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations
8. The TNF receptor 1-associated protein TRADD signals cell death and NF-κ B activation
9. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease
10. Genetic dissection of complex traits: Guidelines for interpreting and reporting linkage results
11. Tumour necrosis factor-α and interferon-γ production measured at the single cell level in normal and inflamed human intestine
12. A test for linkage and association in general pedigrees: The pedigree disequilibrium test
13. Correcting for a potential bias in the pedigree disequilibrium test
14. Scanning chromosome 17 for psoriasis susceptibility. Lack of evidence for a distal 17q locus
15. Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20p) by genomewide scan
16. Localization of psoriasis-susceptibility locus PSORS1 to a 60-kb interval telomeric to HLA-C
17. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease
18. Linkage disequilibrium in the human genome
19. Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci
20. Transmission test for linkage disequilibrium. The insulin gene region and insulin-dependent diabetes mellitus (IDDM)
21. Cell specific effects of glucocorticoid treatment on the NF-κBp65/IκBα system in patients with Crohn's disease
22. Suppression of NF-κB activity by sulfasalazine is mediated by direct inhibition of IκB kinases α and β